Form 4 Filing for NEKTAR THERAPEUTICS
2026-06-18SEC Filing 4 (0001193125-26-276236)
On June 16 and 17, 2026, Robin Howard W, President & CEO of NEKTAR THERAPEUTICS, executed a series of stock sales under a Rule 10b5-1 trading plan. The transactions involved the sale of Common Stock totaling 19990 shares at weighted average prices ranging from $59.97 to $61.65. Following these transactions, the post-transaction shares owned by Mr. W were reported as 69742, 65045, 59545, and 55045 for each respective sale. Additionally, Mr. W holds 28 shares of Common Stock indirectly by spouse. The filing is a Form 4, indicating a change in beneficial ownership.